Article Figures & Data
Figures
- Figure 1
Crude and age-standardized incidence of cancer by sex (A. female, B. male). Data were extracted from Cancer incidence and mortality in China, 20161.
- Figure 2
Crude and age-standardized mortality of cancer by sex (A. female, B. male). Data were extracted from Cancer incidence and mortality in China, 20161.
- Figure 3
Age-standardized 5-year relative survival rates for the common cancers. Data were extracted from Changing cancer survival in China during 2003–2015: a pooled analysis of 17 population-based cancer registries7.
- Figure 4
Measures for cancer prevention and control in China.
Tables
Site Overall Men Women Cases Percentage (%) Rank Cases Percentage (%) Rank Cases Percentage (%) Rank All sites 4,064,000 100.0 – 2,234,300 100.0 – 1,829,600 100.0 – Lung 828,100 20.4 1 549,800 24.6 1 278,300 15.2 2 Colon-rectum 408,000 10.0 2 238,500 10.7 4 169,500 9.3 3 Stomach 396,500 9.8 3 276,300 12.4 3 120,200 6.6 5 Liver 388,800 9.6 4 288,800 12.9 2 100,000 5.5 7 Female breast 306,000 7.5 5 – – – 306,000 16.7 1 Esophagus 252,500 6.2 6 184,500 8.3 5 68,000 3.7 10 Thyroid 202,600 5.0 7 50,000 2.2 12 152,600 8.3 4 All other sites 173,600 4.3 8 90,900 4.1 6 82,700 4.5 8 Cervix 119,300 2.9 9 – – – 119,300 6.5 6 Brain, CNS 109,000 2.7 10 50,500 2.3 11 58,500 3.2 11 Pancreas 100,400 2.5 11 57,000 2.6 9 43,400 2.4 13 Lymphoma 89,900 2.2 12 51,600 2.3 10 38,300 2.1 14 Leukemia 85,800 2.1 13 49,400 2.2 13 36,400 2.0 15 Bladder 82,300 2.0 14 64,200 2.9 8 18,000 1.0 18 Prostate 78,300 1.9 15 78,300 3.5 7 – – – Kidney 75,800 1.9 16 48,000 2.1 14 27,800 1.5 17 Uterus 71,100 1.7 17 – – – 71,100 3.9 9 Ovary 57,200 1.4 18 – – – 57,200 3.1 12 Gallbladder 55,700 1.4 19 26,400 1.2 17 29,300 1.6 16 Lip, oral, cavity, and pharynx 52,200 1.3 20 36,200 1.6 16 16,100 0.9 19 Nasopharynx 52,000 1.3 21 37,400 1.7 15 14,700 0.8 20 Bone 25,800 0.6 22 14,900 0.7 19 10,900 0.6 21 Larynx 25,700 0.6 23 23,500 1.1 18 2,200 0.1 24 Other thoracic organs 13,100 0.3 24 7,600 0.3 20 5,500 0.3 22 Melanoma of skin 7,000 0.2 25 3,500 0.2 21 3,500 0.2 23 Testis 3,400 0.1 26 3,400 0.2 22 – – Cancer incidence and mortality in China, 20161.
Site Overall Men Women Deaths Percentage (%) Rank Deaths Percentage (%) Rank Deaths Percentage (%) Rank All sites 2,413,500 100.0 – 1,530,700 100.0 – 882,800 100.0 – Lung 657,000 27.2 1 454,700 29.7 1 202,300 22.9 1 Liver 336,400 13.9 2 249,600 16.3 2 86,800 9.8 3 Stomach 288,500 12.0 3 200,200 13.1 3 88,400 10.0 2 Colon–rectum 195,600 8.1 4 114,500 7.5 5 81,000 9.2 4 Esophagus 193,900 8.0 5 142,300 9.3 4 51,600 5.8 6 All other sites 93,400 3.9 6 53,500 3.5 6 39,900 4.5 7 Pancreas 87,900 3.6 7 49,800 3.3 7 38,100 4.3 8 Female breast 71,700 3.0 8 – – – 71,700 8.1 5 Brain, CNS 58,500 2.4 9 32,600 2.1 9 25,900 2.9 11 Leukemia 55,700 2.3 10 32,400 2.1 10 23,200 2.6 12 Lymphoma 51,500 2.1 11 31,000 2.0 11 20,500 2.3 14 Gallbladder 41,400 1.7 12 19,500 1.3 14 22,000 2.5 13 Cervix 37,200 1.5 13 – – – 37,200 4.2 9 Bladder 33,700 1.4 14 26,200 1.7 12 7,500 0.9 18 Prostate 33,600 1.4 15 33,600 2.2 8 – – – Ovary 27,200 1.1 16 – – – 27,200 3.1 10 Kidney 26,900 1.1 17 17,100 1.1 16 9,800 1.1 16 Nasopharynx 26,700 1.1 18 19,700 1.3 13 7,000 0.8 19 Lip, oral, cavity, and pharynx 25,800 1.1 19 18,900 1.2 15 6,900 0.8 20 Bone 18,400 0.8 20 10,700 0.7 18 7,700 0.9 17 Uterus 17,100 0.7 21 – – – 17,100 1.9 15 Larynx 14,300 0.6 22 12,500 0.8 17 1,700 0.2 23 Thyroid 8,300 0.3 23 3,100 0.2 20 5,200 0.6 21 Other thoracic organs 6,800 0.3 24 4,300 0.3 19 2,500 0.3 22 Melanoma of skin 3800 0.2 25 2,100 0.1 21 1,700 0.2 24 Testis 900 0.0 26 900 0.1 22 – – – Cancer incidence and mortality in China, 20161.
Year Rural (%) Urban (%) Cancer Heart conditions Cerebrovascular disease Respiratory disease Cancer Heart conditions Cerebrovascular disease Respiratory disease 2000 18.4 12.4 18.4 23.1 24.4 17.7 21.3 13.3 2001 17.7 13.1 19.0 22.5 24.9 17.6 20.4 13.4 2002 20.7 14.3 17.3 15.6 23.5 14.6 17.5 15.6 2003 25.3 12.0 23.8 18.7 25.5 14.4 20.0 14.6 2004 23.7 12.5 14.9 13.3 23.9 18.8 19.1 13.1 2005 20.3 11.8 21.2 23.5 22.9 17.9 21.2 12.6 2006 25.1 13.9 20.4 16.4 27.3 17.1 17.7 13.1 2007 24.8 14.8 20.6 17.2 28.5 16.3 18.0 13.1 2008 25.4 14.1 21.7 16.9 27.1 19.7 19.6 11.9 2009 24.3 17.2 23.2 15.0 27.0 20.8 20.4 10.5 2010 23.1 17.9 23.4 14.2 26.3 20.9 20.2 11.0 2011 23.6 19.4 21.7 13.3 27.8 21.3 20.2 10.6 2012 23.0 18.1 20.6 15.8 26.8 21.5 19.6 12.3 2013 22.4 21.9 22.9 11.5 25.5 21.6 20.3 12.4 2014 23.0 21.7 22.9 12.1 26.2 22.1 20.4 12.0 2015 23.2 21.8 23.2 12.1 26.4 22.0 20.6 11.8 2016 22.9 22.2 23.3 12.0 26.1 22.6 20.6 11.2 2017 23.1 22.7 23.2 11.6 26.1 23.0 20.6 10.9 2018 23.0 23.5 23.2 11.2 26.0 23.3 20.5 10.8 2019 23.3 23.8 22.9 10.8 25.7 23.7 20.6 10.4 2020 23.1 24.5 23.5 9.1 25.4 24.6 21.3 8.7 National Bureau of Statistics of China.
1973–1975 (year) 1990–1992 (year) 2004–2005 (year) Site Proportion (%) Site Proportion (%) Site Proportion (%) Stomach 23.0 Stomach 23.2 Lung 22.7 Esophagus 22.3 Liver 18.8 Liver 19.3 Liver 15.1 Lung 16.2 Stomach 18.2 Cervix 7.6 Esophagus 16.1 Esophagus 11.2 Lung 7.4 Colorectum 4.9 Colorectum 5.2 Colorectum 5.3 Leukemia 3.4 Leukemia 2.8 Leukemia 3.8 Cervix 1.8 Brain 2.3 Nasopharynx 2.8 Nasopharynx 1.6 Breast 2.1 Breast 2.0 Breast 1.6 Pancreas 1.9 Brain 1.9 Bladder 0.9 Bone 1.3 Others 8.8 Others 11.5 Others 13.0 Three National Retrospective Sampling Survey of Death Causes6.
In this issue
Jump to section
- Article
- Abstract
- Introduction
- Cancer epidemiology
- Etiology and underlying modifiable risk factors
- Cancer prevention and control
- Expenditures and national insurance for cancer control
- Limitations and challenges in cancer prevention
- Grant support
- Conflict of interest statement
- Author contributions
- Acknowledgments
- References
- Figures & Data
- Info & Metrics
- References
Related Articles
Cited By...
- Social inequalities on Cancer Incidence and Mortality in a Brazilian City
- Erianin inhibits the proliferation of lung cancer cells by suppressing mTOR activation and disrupting pyrimidine metabolism
- Nomogram based on the log odds of negative lymph node/T stage can predict the prognosis of patients with colorectal cancer: a retrospective study based on SEER database and external validation in China
- Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancer
- The role of reactive oxygen species in gastric cancer
- Impact of cancer diagnosis on life expectancy by area-level socioeconomic groups in New South Wales, Australia: a population-based study
- Esophageal cancer global burden profiles, trends, and contributors
- Modeling human gastric cancers in immunocompetent mice
- Advances in MET tyrosine kinase inhibitors in gastric cancer
- Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma
- Influence of sex on outcomes of liver transplantation for hepatocellular carcinoma: a multicenter cohort study in China
- Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies
- Bronchoalveolar lavage fluid assessment facilitates precision medicine for lung cancer
- A retrospective analysis of mature T- and NK-cell lymphomas
- Cervical cancer prevention in China: where are we now, and whats next?
- Cancer-educated neutrophils promote lung cancer progression via PARP-1-ALOX5-mediated MMP-9 expression
- DNA methylation biomarkers for early detection of gastric and colorectal cancers
- Treatment strategies for patients with HER2-positive gastric cancer
- Current therapeutic landscape and resistance mechanisms to larotrectinib
- Single-arm trials for domestic oncology drug approvals in China
- Cohort profile: design and methods of the Chinese colorectal, breast, lung, liver, and stomach cancer screening trial (C-BLAST)
- Targeting endoplasmic reticulum stress signaling in ovarian cancer therapy
- The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer
- Regulatory role of exosomes in colorectal cancer progression and potential as biomarkers
- Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma
- The Hippo/YAP signaling pathway: the driver of cancer metastasis
- Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance
- Development of glioblastoma organoids and their applications in personalized therapy
- Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer
- Smart drug delivery systems to overcome drug resistance in cancer immunotherapy
- Smart drug delivery systems to overcome drug resistance in cancer immunotherapy
- Early detection of gastric cancer in China: progress and opportunities